Thunderbird Partners LLP Purchases New Position in Illumina, Inc. (NASDAQ:ILMN)

Thunderbird Partners LLP bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 88,824 shares of the life sciences company's stock, valued at approximately $11,870,000. Illumina accounts for approximately 19.2% of Thunderbird Partners LLP's investment portfolio, making the stock its 3rd largest holding. Thunderbird Partners LLP owned 0.06% of Illumina as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Stifel Financial Corp increased its stake in shares of Illumina by 24.9% in the 4th quarter. Stifel Financial Corp now owns 326,140 shares of the life sciences company's stock valued at $43,582,000 after acquiring an additional 64,986 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Illumina by 188.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 13,373 shares of the life sciences company's stock valued at $1,787,000 after acquiring an additional 8,739 shares during the last quarter. Transatlantique Private Wealth LLC bought a new stake in shares of Illumina in the 4th quarter valued at about $215,000. MML Investors Services LLC increased its stake in shares of Illumina by 10.8% in the 4th quarter. MML Investors Services LLC now owns 25,888 shares of the life sciences company's stock valued at $3,459,000 after acquiring an additional 2,515 shares during the last quarter. Finally, Natixis bought a new stake in shares of Illumina in the 4th quarter valued at about $174,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Piper Sandler upped their price target on Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Guggenheim lowered their target price on Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Royal Bank of Canada lowered their target price on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday, April 8th. TD Cowen cut Illumina from a "buy" rating to a "hold" rating and lowered their target price for the stock from $177.00 to $140.00 in a research note on Friday, February 7th. Finally, Hsbc Global Res cut Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $138.70.

Illumina Stock Down 0.3 %

NASDAQ:ILMN traded down $0.26 on Friday, hitting $77.35. 1,424,483 shares of the company's stock were exchanged, compared to its average volume of 2,286,599. The firm has a 50-day moving average price of $82.02 and a 200-day moving average price of $117.87. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The company has a market cap of $12.24 billion, a P/E ratio of -10.07, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.